Actively Recruiting
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Led by Beijing GoBroad Hospital · Updated on 2025-08-20
48
Participants Needed
3
Research Sites
173 weeks
Total Duration
On this page
Sponsors
B
Beijing GoBroad Hospital
Lead Sponsor
F
First Affiliated Hospital of Wenzhou Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LUCAR-E9D,LUCAR-E9K, a dual-targeted cell preparation targeting CD19/CD20, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
CONDITIONS
Official Title
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Understands the risks and benefits and agrees to participate with signed consent
- Aged between 18 and 75 years
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Histologically confirmed B-cell non-Hodgkin lymphoma expressing CD19 and/or CD20
- At least one measurable tumor lesion as per Lugano 2014 criteria
- Primary refractory disease or relapse within 12 months after first-line treatment
- Life expectancy of at least 3 months
- Negative pregnancy test for women of childbearing potential before treatment
You will not qualify if you...
- Diagnosis or treatment for other invasive cancers besides B-cell non-Hodgkin lymphoma
- Active acute or chronic graft-versus-host disease, except mild skin involvement
- Active central nervous system involvement; remission from prior CNS infiltration is allowed
- Significant bleeding disorders
- Use of steroids or immunosuppressants for chronic diseases, except specified exceptions
- Severe infections or uncontrolled fungal infections
- Active or unstable autoimmune diseases or autoimmune diseases with relapse risk within the last 3 years
- Breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Hefei, China
Actively Recruiting
2
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Actively Recruiting
3
Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
Actively Recruiting
Research Team
K
Kai Hu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here